Drug Database · Clinicians

Olmesartan

Brands (25) Alzor, Olazura, Olmetec…Show all

US brand (reference label): Benicar; not a Philippine-registered brand.

Angiotensin II receptor blocker (ARB); Angiotensin II antagonist; and others PH FDA category

Rx · Prescription drug45 PH productsVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df, version date September 23, 2025 (Benicar · Cosette Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Benicar is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Benicar is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs.

There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.

The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.

Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).

These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. Benicar is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adult and pediatric patients six years of age and older, alone or with other antihypertensive agents, to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1).

Contraindications

4 CONTRAINDICATIONS Do not co-administer aliskiren with Benicar in patients with diabetes [see Drug Interactions (7.3)]. Do not co-administer aliskiren with Benicar in patients with diabetes (4).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Indication Starting Dose Dose Range Adult Hypertension (2.1)
  • 20 mg once daily 20 - 40 mg once daily Pediatric Hypertension (6 years of age and older) (2.2)
  • 20 to <35 kg 20 to <35 kg 10 mg once daily 10 - 20 mg once daily ≥ 35 kg ≥ 35 kg 20 mg once daily 20 - 40 mg once daily
2.1 Adult Hypertension

2.1 Adult Hypertension Dosage must be individualized. The usual recommended starting dose of Benicar is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect.

Twice-daily dosing offers no advantage over the same total dose given once daily. For patients with possible depletion of intravascular volume (e.g., patients treated with diuretics, particularly those with impaired renal function), initiate Benicar under close medical supervision and give consideration to use of a lower starting dose [see Warnings and Precautions (5.3)].

2.2 Pediatric Hypertension (6 Years of Age and Older)

2.2 Pediatric Hypertension (6 Years of Age and Older) Dosage must be individualized. For children who can swallow tablets, the usual recommended starting dose of Benicar is 10 mg once daily for patients who weigh 20 to <35 kg (44 to 77 lb), or 20 mg once daily for patients who weigh ≥35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to a maximum of 20 mg once daily for patients who weigh <35 kg or 40 mg once daily for patients who weigh ≥35 kg.

Use of Benicar in children <1 year of age is not recommended [see Warnings and Precautions (5.2) and Use in Specific Populations (8.4)]. For children who cannot swallow tablets, the same dose can be given using an extemporaneous suspension as described below [see Clinical Pharmacology (12.3)]. Follow the suspension preparation instructions below to administer Benicar as a suspension.

Preparation of Suspension (for 200 mL of a 2 mg/mL suspension) Add 50 mL of Purified Water to an amber polyethylene terephthalate (PET) bottle containing twenty Benicar 20 mg tablets and allow to stand for a minimum of 5 minutes. Shake the container for at least 1 minute and allow the suspension to stand for at least 1 minute.

Repeat 1-minute shaking and 1-minute standing for four additional times. Add 100 mL of ORA-Sweet ® and 50 mL of ORA-Plus ®* to the suspension and shake well for at least 1 minute. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 4 weeks. Shake the suspension well before each use and return promptly to the refrigerator. * ORA-Sweet ® and ORA-Plus ® are registered trademarks of Paddock Laboratories, Inc.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.7 Renal Impairment Patients with renal insufficiency have elevated serum concentrations of olmesartan compared to subjects with normal renal function. After repeated dosing, the AUC was approximately tripled in patients with severe renal impairment (creatinine clearance <20 mL/min). No initial dosage adjustment is recommended for patients with moderate to marked renal impairment (creatinine clearance <40 mL/min) [see Dosage and Administration (2.1), Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].

Patients with Renal Impairment In patients with renal insufficiency, serum concentrations of olmesartan were elevated compared to subjects with normal renal function. After repeated dosing, the AUC was approximately tripled in patients with severe renal impairment (creatinine clearance <20 mL/min). The pharmacokinetics of olmesartan in patients undergoing hemodialysis has not been studied [see Dosage and Administration (2.1), Warnings and Precautions (5.4) and Use in Specific Populations (8.7)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Increases in AUC 0-∞ and C max were observed in patients with moderate hepatic impairment compared to those in matched controls, with an increase in AUC of about 60%. No initial dosage adjustment is recommended for patients with moderate to marked hepatic dysfunction [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The antihypertensive effects of Benicar were evaluated in one randomized, double-blind clinical study in pediatric patients 1 to 16 years of age [see Clinical Studies (14.2)]. The pharmacokinetics of Benicar were evaluated in pediatric patients 1 to 16 years of age [see Clinical Pharmacology (12.3)]. Benicar was generally well tolerated in pediatric patients, and the adverse experience profile was similar to that described for adults.

Benicar has not been shown to be effective for hypertension in children <6 years of age. Use of Benicar in children <1 year of age is not recommended [see Warnings and Precautions (5.2)]. The renin-angiotensin-aldosterone system (RAAS) plays a critical role in kidney development. RAAS blockade has been shown to lead to abnormal kidney development in very young mice.

Administering drugs that act directly on the renin- angiotensin aldosterone system (RAAS) can alter normal renal development.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of hypertensive patients receiving Benicar in clinical studies, more than 20% were 65 years of age and over, while more than 5% were 75 years of age and older. No overall differences in effectiveness or safety were observed between elderly patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].

Dosage forms

Philippines

  • Film-coated tablet: 10 mg, 20 mg, 40 mg
  • Tablet: 20 mg, 40 mg
  • Film–coated tablet: 20 mg, 40 mg
  • Film – coated tablet: 20 mg

Registered products in the Philippines

45 products registered with the Food and Drug Administration (FDA) Philippines list Olmesartan as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Olmesartan Medoximil (2 products). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products45
Philippine FDA-registered products for Olmesartan
Package insert
AlzorOlmesartan medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY36779
Oct 12, 2029
AlzorOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY47888
Mar 23, 2031
AlzorOlmesartan Medoxomil
20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY48761
Jun 6, 2028
AlzorOlmesartan medoxomil
40 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY36778
Mar 19, 2031
AlzorOlmesartan Medoxomil
40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY48760
Jun 6, 2028
CresartOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Lek Pharmaceuticals D.D.Slovenia
Importer: Sandoz Philippines Corporation
DRP-3629
Feb 27, 2027
CresartOlmesartan Medoxomil
40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Lek Pharmaceuticals D.D.Slovenia
Importer: Sandoz Philippines Corporation
DRP-3630
Feb 27, 2027
MelostarOlmesartan medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Trumed PharmaceuticalsImporter: AMB HK Enterprises, Inc.
DRP-12339-02
Jul 20, 2027
NoneOlmesartan medoxomil
20 mg Film – Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-4864-01
Oct 24, 2028
NoneOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-4814
Oct 11, 2028
NoneOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-4814-01
Oct 11, 2028
NoneOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
International Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-4814-02
Oct 11, 2028
NoneOlmesartan Medoxomil
40 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DR-XY40491
Jan 3, 2027
NoneOlmesartan Medoxomil
40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-4817
Oct 14, 2028
NoneOlmesartan Medoxomil
40 mg tabletAlu/Alu PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.Importer: TGP Pharma Inc.
DRP-7967-01
Mar 26, 2027
Ojos-20Olmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4602-01
Aug 8, 2028
Ojos-40Olmesartan Medoxomil
40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4601-01
Aug 27, 2028
OlazuraOlmesartan Medoxomil
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12340
Jul 20, 2027
OlazuraOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12339
Jul 20, 2027
OlazuraOlmesartan medoxomil
40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12410
Aug 2, 2027
OldomilOlmesartan medoxomil
20 mg Film–Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-4864
Oct 24, 2028
OldomilOlmesartan medoxomil
40 mg Film–Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-4863
Oct 24, 2028
OlmatOlmesartan Medoxomil
20 mg tabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-7895
Mar 19, 2032
OlmatOlmesartan Medoxomil
40 mg tabletAlu/Alu PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-7967
Mar 26, 2032
Olmax-20Olmesartan
20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Dreamax Incorporated
DRP-13333
Jan 27, 2028
Olmax-40Olmesartan Medoxomil
40mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Dreamax Incorporated
DRP-13306
Jan 23, 2028
Olmecor-20Olmesartan MedoximilVariant spelling
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
TORRENT PHARMACEUTICALS LIMITEDIndia
TORRENT PHARMA PHILIPPINES, INC.
DR-XY42452
Sep 2, 2028
Olmecor-40Olmesartan Medoxomil
40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
TORRENT PHARMACEUTICALS LTD.India
TORRENT PHARMA PHILIPPINES, INC.
DR-XY42451
Sep 2, 2028
Olmenov-20Olmesartan Medoxomil
20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Medinova Pharmaceutical, Inc.
DRP-12938
Nov 4, 2027
Olmenov-40Olmesartan MedoximilVariant spelling
40mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Evertogen Life Sciences LimitedIndia
Importer: Medinova Pharmaceutical, Inc.
DRP-11023
Apr 6, 2027
OlmepasOlmesartan Medoxomil
20 mg Film coated tabletAlu/ALu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY44278
Mar 11, 2030
Olmephil 10Olmesartan medoxomil
10 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-12340-01
Jul 20, 2027
Olmephil 20Olmesartan medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-12339-01
Jul 20, 2027
OlmesolvOlmesartan medoxomil
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-10564
Oct 20, 2031
OlmesolvOlmesartan medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-10565
Oct 20, 2031
Olmespec 20Olmesartan Medoxomil
20 mg Film - Coated TabletTriple Laminated Cold Formable PA/Alu/PVC Film/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Aurobindo Pharma Limited Unit VIIIndia
AAA Pharma, Inc.
DR-XY48955
Dec 21, 2028
Olmespec 40Olmesartan medoxomil
40mg Film - Coated TabletTriple Laminated Cold Formable PA/Alu/PVC Film/Alu lister Pack Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Aurobindo Pharma Limited Unit VIIIndia
AAA Pharma, Inc.
DR-XY48954
Dec 21, 2028
OlmestanOlmesartan medoxomil
20 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-17148
Oct 7, 2030
OlmetecOlmesartan medoxomil
10 mg Film-Coated TabletAlu/Alu blister pack x 10's Box of 30's
RxVAT-exempt
Daiichi Sankyo Europe GmbHGermany
Importer: Pfizer, Inc.
DRP-3449
Sep 22, 2028
OlmetecOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 1's [Box of 1's (Physician's Sample)]; Alu/Alu Blister Pack x 2's [Box of 2's (Physician's Sample)]
RxVAT-exempt
Daiichi Sankyo Europe GmbHGermany
Importer: Pfizer, Inc.
DRP-3448
Sep 22, 2028
OlmetecOlmesartan medoxomil
40 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Daiichi Sankyo Europe GmbHGermany
Importer: Pfizer, Inc.
DRP-3450
Sep 22, 2028
OlmexlOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Phil Asia Pharma Inc.Importer: Ambica International Corporation
DRP-4602
Aug 8, 2028
Olmexl-40Olmesartan Medoxomil
40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Phil Asia Pharma IncImporter: Ambica International Corporation
DRP-4601
Aug 27, 2028
OlmezarOlmesartan medoxomil
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Micro Labs LimitedIndia
OEP Philippines, Inc.Importer: Brown & Burk Phils., Inc.
DRP-7895-01
Mar 19, 2027
UnbrandedOlmesartan Medoxomil
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Lek Pharmaceuticals D.D.Slovenia
Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation
DRP-3629-01
Feb 27, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 5 mg yellow, round, film-coated, non-scored tablets debossed with C12 on one side and plain on the other side 20 mg white, round, film-coated, non-scored tablets debossed with C14 on one side and plain on the other side 40 mg white, oval-shaped, film-coated, non-scored tablets debossed with C15 on one side and plain on the other side Tablets: 5 mg, 20 mg, and 40 mg (3).

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

Avoid fetal (in utero) exposure (5.1). Use of Benicar in children <1 year of age is not recommended (5.2). Observe for signs and symptoms of hypotension in volume- or salt-depleted patients with treatment initiation (5.3). Monitor for worsening renal function in patients with renal impairment (5.4). Sprue-like enteropathy has been reported.

Consider alternative antihypertensive therapy in cases where no other etiology is found (5.5).

5.1 Fetal Toxicity

5.1 Fetal Toxicity Benicar can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system (RAS) during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.

Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Benicar as soon as possible [see Use in Specific Populations (8.1)].

5.2 Morbidity in Infants Use

5.2 Morbidity in Infants Use of Benicar in children <1 year of age is not recommended. Drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) can have effects on the development of immature kidneys [see Use in Specific Populations (8.4)].

5.3 Hypotension in Volume- or Salt-Depleted Patients

5.3 Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. Initiate treatment under close medical supervision and consider starting at a lower dose.

If hypotension does occur, place the patient in the supine position and, if necessary, give an intravenous infusion of normal saline [see Dosage and Administration (2.1)]. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.

5.4 Impaired Renal Function

5.4 Impaired Renal Function As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Benicar. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

Similar results may be anticipated in patients treated with Benicar [see Dosage and Administration (2.1), Drug Interactions (7.3), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported.

There has been no long-term use of Benicar in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.

5.5 Sprue-like Enteropathy

5.5 Sprue-like Enteropathy Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies.

Consider alternative antihypertensive therapy in cases where no other etiology is identified.

5.6 Hyperkalemia

5.6 Hyperkalemia Serum potassium should be monitored in patients receiving Benicar. Drugs that inhibit the renin angiotensin system can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3)].

Drug interactions

Drug interactions (US label) US FDA label

Agents increasing potassium levels may lead to increase in serum potassium (7.1). NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.2). Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.3). Lithium: Increases in serum lithium concentrations and lithium toxicity (7.4).

Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose (7.5).

7.1 Agents Increasing Serum Potassium

7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium. If co-medication is considered necessary, monitoring of serum potassium is advisable.

7.2 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors…

7.2 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.

Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil, may be attenuated by NSAIDs including selective COX-2 inhibitors.

7.3 Dual Blockade of the Renin-Angiotensin System (RAS)

7.3 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Benicar and other agents that affect the RAS. Do not co-administer aliskiren with Benicar in patients with diabetes [see Contraindications (4)]. Avoid use of aliskiren with Benicar in patients with renal impairment (GFR <60 ml/min).

7.4 Lithium

7.4 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including BENICAR. Monitor serum lithium levels during concomitant use.

7.5 Colesevelam Hydrochloride

7.5 Colesevelam Hydrochloride Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. Administration of olmesartan at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose [see Clinical Pharmacology (12.3)].

Adverse reactions

Adverse reactions (US label) US FDA label

The most common adverse reaction in adults was dizziness (3%) (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adult Hypertension Benicar has been evaluated for safety in more than 3825 patients/subjects, including more than 3275 patients treated for hypertension in controlled trials.

This experience included about 900 patients treated for at least 6 months and more than 525 for at least 1 year. Events generally were mild, transient and had no relationship to the dose of Benicar. Analysis of gender, age and race groups demonstrated no differences between Benicar and placebo-treated patients. The rate of withdrawals due to adverse reactions in all trials of hypertensive patients was 2.4% (i.e., 79/3278) of patients treated with Benicar and 2.7% (i.e., 32/1179) of control patients.

In placebo-controlled trials, the only adverse reaction that occurred in more than 1% of patients treated with Benicar and at a higher incidence versus placebo was dizziness (3% vs. 1%). Facial edema was reported in five patients receiving Benicar. Angioedema has been reported with angiotensin II antagonists. Pediatric Hypertension No relevant differences were identified between the adverse experience profile for pediatric patients aged 1 to 16 years and that previously reported for adult patients.

6.2 Post-Marketing Experience

6.2 Post-Marketing Experience The following adverse reactions have been reported in post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole: Asthenia, angioedema, anaphylactic reactions Gastrointestinal: Vomiting, sprue-like enteropathy [see Warnings and Precautions (5.5)] Metabolic and Nutritional Disorders: Hyperkalemia Musculoskeletal: Rhabdomyolysis Urogenital System: Acute renal failure, increased blood creatinine levels Skin and Appendages: Alopecia, pruritus, urticaria Data from one controlled trial and an epidemiologic study have suggested that high-dose olmesartan may increase cardiovascular (CV) risk in diabetic patients, but the overall data are not conclusive.

The randomized, placebo-controlled, double-blind ROADMAP trial (Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention trial, n=4447) examined the use of olmesartan, 40 mg daily, vs. placebo in patients with type 2 diabetes mellitus, normoalbuminuria, and at least one additional risk factor for CV disease. The trial met its primary endpoint, delayed onset of microalbuminuria, but olmesartan had no beneficial effect on decline in glomerular filtration rate (GFR).

There was a finding of increased CV mortality (adjudicated sudden cardiac death, fatal myocardial infarction, fatal stroke, revascularization death) in the olmesartan group compared to the placebo group (15 olmesartan vs. 3 placebo, HR 4.9, 95% confidence interval [CI], 1.4, 17), but the risk of non-fatal myocardial infarction was lower with olmesartan (HR 0.64, 95% CI 0.35, 1.18). The epidemiologic study included patients 65 years and older with overall exposure of > 300,000 patient-years.

In the sub-group of diabetic patients receiving high-dose olmesartan (40 mg/d) for > 6 months, there appeared to be an increased risk of death (HR 2.0, 95% CI 1.1, 3.8) compared to similar patients taking other angiotensin receptor blockers. In contrast, high-dose olmesartan use in non-diabetic patients appeared to be associated with a decreased risk of death (HR 0.46, 95% CI 0.24, 0.86) compared to similar patients taking other angiotensin receptor blockers.

No differences were observed between the groups receiving lower doses of olmesartan compared to other angiotensin blockers or those receiving therapy for < 6 months. Overall, these data raise a concern of a possible increased CV risk associated with the use of high-dose olmesartan in diabetic patients. There are, however, concerns with the credibility of the finding of increased CV risk, notably the observation in the large epidemiologic study for a survival benefit in non-diabetics of a magnitude similar to the adverse finding in diabetics.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Benicar can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.

In animal reproduction studies, Benicar treatment during organogenesis resulted in increased embryofetal toxicity in rats at doses lower than maternally toxic doses. When pregnancy is detected, discontinue Benicar as soon as possible. Consider alternative antihypertensive therapy during pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death.

In patients taking Benicar during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of gestation. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Closely observe infants with histories of in utero exposure to Benicar for hypotension, oliguria, and hyperkalemia. In neonates with a history of in utero exposure to Benicar, if oliguria or hypotension occurs, utilize measures to maintain adequate blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and supporting renal function.

Data Animal Data No teratogenic effects were observed when olmesartan medoxomil was administered to pregnant rats at oral doses up to 1000 mg/kg/day (240 times the maximum recommended human dose (MRHD) on a mg/m 2 basis) or pregnant rabbits at oral doses up to 1 mg/kg/day (half the MRHD on a mg/m 2 basis; higher doses could not be evaluated for effects on fetal development as they were lethal to the does). In rats, significant decreases in pup birth weight and weight gain were observed at doses ≥1.6 mg/kg/day, and delays in developmental milestones (delayed separation of ear auricula, eruption of lower incisors, appearance of abdominal hair, descent of testes, and separation of eyelids) and dose-dependent increases in the incidence of dilation of the renal pelvis were observed at doses ≥ 8 mg/kg/day.

The no observed effect dose for developmental toxicity in rats is 0.3 mg/kg/day, about one-tenth the MRHD of 40 mg/day.

Mechanism of action

12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium.

Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis. An AT 2 receptor is found also in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis.

Olmesartan has more than a 12,500-fold greater affinity for the AT 1 receptor than for the AT 2 receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is a mechanism of many drugs used to treat hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.

Because olmesartan medoxomil does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Benicar doses of 2.5 mg to 40 mg inhibit the pressor effects of angiotensin I infusion. The duration of the inhibitory effect was related to dose, with doses of Benicar >40 mg giving >90% inhibition at 24 hours. Plasma concentrations of angiotensin I and angiotensin II and plasma renin activity (PRA) increase after single and repeated administration of Benicar to healthy subjects and hypertensive patients. Repeated administration of up to 80 mg Benicar had minimal influence on aldosterone levels and no effect on serum potassium.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Metabolism and Excretion Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, there is virtually no further metabolism of olmesartan.

Total plasma clearance of olmesartan is 1.3 L/h, with a renal clearance of 0.6 L/h.

Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Olmesartan medoxomil is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. Benicar tablets and the suspension formulation prepared from Benicar tablets are bioequivalent [see Dosage and Administration (2.2)]. The absolute bioavailability of olmesartan is approximately 26%.

After oral administration, the peak plasma concentration (C max) of olmesartan is reached after 1 to 2 hours. Food does not affect the bioavailability of olmesartan. Benicar may be administered with or without food. Distribution The volume of distribution of olmesartan is approximately 17 L. Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.

The protein binding is constant at plasma olmesartan concentrations well above the range achieved with recommended doses. In rats, olmesartan crossed the blood-brain barrier poorly, if at all. Olmesartan passed across the placental barrier in rats and was distributed to the fetus. Olmesartan was distributed to milk at low levels in rats.

Metabolism and Excretion Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, there is virtually no further metabolism of olmesartan. Total plasma clearance of olmesartan is 1.3 L/h, with a renal clearance of 0.6 L/h. Approximately 35% to 50% of the absorbed dose is recovered in urine while the remainder is eliminated in feces via the bile.

Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours. Olmesartan shows linear pharmacokinetics following single oral doses of up to 320 mg and multiple oral doses of up to 80 mg. Steady-state levels of olmesartan are achieved within 3 to 5 days and no accumulation in plasma occurs with once-daily dosing.

Specific Populations Geriatric Patients The pharmacokinetics of olmesartan were studied in the elderly (≥65 years). Overall, maximum plasma concentrations of olmesartan were similar in young adults and the elderly. Modest accumulation of olmesartan was observed in the elderly with repeated dosing; AUC ss, τ was 33% higher in elderly patients, corresponding to an approximate 30% reduction in CL R [see Dosage and Administration (2.1) and Use in Specific Populations (8.5)].

Pediatric Patients The pharmacokinetics of olmesartan were studied in pediatric hypertensive patients aged 1 to 16 years. The clearance of olmesartan in pediatric patients was similar to that in adult patients when adjusted by the body weight [see Use in Specific Populations (8.4)]. Olmesartan pharmacokinetics have not been investigated in pediatric patients less than 1 year of age [see Warnings and Precautions (5.2) and Use in Specific Populations (8.4)].

Male and Female Patients Minor differences were observed in the pharmacokinetics of olmesartan in women compared to men. AUC and C max were 10-15% higher in women than in men. Patients with Hepatic Impairment Increases in AUC 0-∞ and C max were observed in patients with moderate hepatic impairment compared to those in matched controls, with an increase in AUC of about 60% [see Dosage and Administration (2.1) and Use in Specific Populations (8.6)].

Patients with Renal Impairment In patients with renal insufficiency, serum concentrations of olmesartan were elevated compared to subjects with normal renal function. After repeated dosing, the AUC was approximately tripled in patients with severe renal impairment (creatinine clearance <20 mL/min). The pharmacokinetics of olmesartan in patients undergoing hemodialysis has not been studied [see Dosage and Administration (2.1), Warnings and Precautions (5.4) and Use in Specific Populations (8.7)].

Drug Interaction Studies Bile Acid Sequestering Agent Colesevelam Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in C max and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in C max and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride [see Drug Interactions (7.5)].

Other Studies No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH) 3 /Mg(OH) 2]. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce, or are metabolized by those enzymes are not expected.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Benicar · Cosette Pharmaceuticals, Inc. [US FDA-approved label, version 1, September 23, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .